Galcanezumab effectively treats episodic or chronic migraine after multiple standard of care preventive medication failures.
The Food and Drug Administration has accepted for review the supplemental New Drug Application for rimegepant (Nurtec™ ODT; Biohaven) for the preventive treatment of migraine.
Neurologic manifestations are common in COVID-19, occurring in 82.3 percent of hospitalized patients.
Previously, the external trigeminal nerve stimulator was only available with a prescription.
Repetitive intravenous dihydroergotamine may be an effective therapy for children with status migrainous or chronic migraine, but without lasting benefit.
During the study, 50 migraine patients randomly received either topically applied timolol maleate ophthalmic solution, 0.5%, or placebo eyedrops.
Migraine is more common among sexual-minority groups than individuals identifying as exclusively heterosexual.
While there was no universal one, red flags concerning prior medical history were present in almost all patients with COVID-19 who developed headache.
Headache may be an early symptom of COVID-19, and identifying patients with characteristic features may help provide early isolation and treatment.
Protective parenting behavior is associated with significantly greater frequency of adolescent headaches.